Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research
Por:
Gianella, S, Lauring, AS, Paredes, R, Croda, J, Andes, D, Uhlemann, AC, Chew, KW, Stephenson, KE, Lewnard, JA, John, ARO, Leung, DT, Clancy, CJ, Chu, HY, Sears, CL and Li, JZ
Publicada:
24 feb 2026
Ahead of Print:
1 feb 2026
Resumen:
Despite transformative advances in antiretroviral therapy, human immunodeficiency virus (HIV) remains a lifelong condition driven by durable viral reservoirs, chronic immune dysfunction, and complex interactions with host biology, coinfections, and aging. While implementation science is essential to ensure that effective interventions reach populations most affected by HIV, implementation cannot succeed in isolation from continued discovery or from the political and social contexts in which care is delivered. This editorial highlights critical gaps in our understanding of sex-based immunologic differences, tissue-specific viral persistence, resistance evolution, and the long-term inflammatory and metabolic consequences of treated HIV-gaps that directly constrain the durability, equity, and scalability of prevention, treatment, and cure strategies. We further emphasize that successful translation depends on stable policy environments, sustained public investment, and trust-based partnerships with affected communities, without which even highly effective biomedical advances fail to achieve impact. Sustained investment across the full translational spectrum-from basic and mechanistic science through clinical, behavioral, and implementation research-is therefore essential. HIV research has repeatedly served as a model system driving advances across immunology, vaccinology, oncology, aging, and pandemic preparedness, underscoring its broader relevance to human infectious diseases.
Filiaciones:
Gianella, S:
Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, Dept Med, La Jolla, CA USA
Lauring, AS:
Univ Michigan, Med Sch, Dept Internal Med, Div Infect Dis, Ann Arbor, MI USA
:
Hosp Germans Trias I Pujol, Infect Dis Dept, Barcelona, Catalonia, Spain
IrsiCaixa AIDS Res Inst, Barcelona, Catalonia, Spain
Croda, J:
Fiocruz Mato Grosso Do Sul, Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil
Univ Fed Mato Grosso Do Sul, Fac Med, Campo Grande, Brazil
Andes, D:
Univ Wisconsin, Dept Med, Div Infect Dis, Madison, WI USA
Univ Wisconsin, Dept Med Microbiol & Immunol, Div Infect Dis, Madison, WI USA
Uhlemann, AC:
Columbia Univ, Irving Med Ctr, Div Infect Dis, New York, NY USA
Chew, KW:
UCLA, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA USA
UCLA, Ctr Clin AIDS Res & Educ CARE, David Geffen Sch Med, Los Angeles, CA USA
Stephenson, KE:
Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA USA
Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA USA
Lewnard, JA:
Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA USA
Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA USA
John, ARO:
Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA USA
Univ Penn, Perelman Sch Med, Philadelphia, PA USA
Leung, DT:
Univ Utah, Sch Med, Dept Internal Med, Div Infect Dis, Salt Lake City, UT USA
Clancy, CJ:
Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA
Chu, HY:
Univ Washington, Sch Med & Publ Hlth, Dept Med, Seattle, WA USA
Univ Washington, Sch Med & Publ Hlth, Dept Epidemiol, Seattle, WA USA
Sears, CL:
Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD USA
Li, JZ:
Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA USA
|